January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Jan 16, 2025, 22:20

Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma

Svetlana Nikic shared on LinkedIn:

“New data just out from TRACERx in Nature Medicine showing that even very low traces of pre-operative ctDNA detected by Personalis, Inc. NeXT Personal (whole genome-based approach) may be linked to increased recurrence risk in patients with early-stage lung adenocarcinoma, and is associated with worse clinical outcomes compared with ctDNA-negative patients.

Prospective studies are needed to show the clinical utility and ultimately impact on patient outcomes, but indeed promising data in the early-stage setting.

Congratulations Charles Swanton and the rest of TRACERx team!”

Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma | Nature Medicine

Authors: James R. M. Black, Gabor Bartha, Charles W. Abbott, Sean M. Boyle, Takahiro Karasaki, Bailiang Li, Rui Chen, Jason Harris, Selvaraju Veeriah, Martina Colopi, Maise Al Bakir, Wing Kin Liu, John Lyle, Fábio C. P. Navarro, Josette Northcott, Rachel Marty Pyke, Mark S. Hill, Kerstin Thol, Ariana Huebner, Chris Bailey, Emma C. Colliver, Carlos Martínez-Ruiz, Kristiana Grigoriadis, Piotr Pawlik, David A. Moore, Daniele Marinelli, Oliver G. Shutkever, Cian Murphy, Monica Sivakumar, TRACERx consortium, Jacqui A. Shaw, Allan Hackshaw, Nicholas McGranahan, Mariam Jamal-Hanjani, Alexander M. Frankell, Richard O. Chen, Charles Swanton.

Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma

Svetlana Nikic is the Founder of Precision Oncology Consulting. With a background including roles at Roche Diagnostics and Illumina, she focuses on advancing molecular methods in clinical settings. Svetlana spearheaded initiatives to integrate genomics-based approaches like whole-genome sequencing into oncology routine testing. Her achievements include establishing an oncology expert network and supporting the introduction of advanced genomic analysis in Swedish leukemia patient care. Svetlana holds advanced degrees in biochemistry, molecular biology, and marketing management, currently pursuing Harvard Medical School courses in Clinical Drug Development and Pharmacology.